{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:26:42Z","timestamp":1782775602827,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alexion GK"},{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eculizumab has been approved for atypical haemolytic-uraemic syndrome (aHUS) in Japan since 2013. Post-marketing surveillance enrolled patients with aHUS who received\u2009\u2265\u20091 dose of eculizumab to assess eculizumab safety and effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated serious adverse events and effectiveness endpoints, i.e., haematologic normalization, a decrease of\u2009\u2265\u200925% in serum creatinine (sCr) levels, and complete thrombotic microangiopathy (TMA) response in adult patients with aHUS without other\u00a0underlying diseases. In addition, the difference of baseline characteristics between patients who did and did not meet effectiveness endpoints was examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this safety and effectiveness analysis, 79 adult patients were included; median age was 54.0\u00a0years, median treatment duration was 30\u00a0weeks. Total exposure time of eculizumab was 75.51 patient-years, and 94 serious adverse events were reported in 39 patients. No unexpected safety signals were identified in this population. Mean platelet count, lactate dehydrogenase and estimated glomerular filtration rate significantly improved after 7\u00a0days\u00a0of treatment. Complete TMA response, haematologic normalization and the improvement of sCr levels were met by 35.3%, 40.4% and 51.3% of patients, respectively. Median treatment duration was shorter in patients who did not achieve complete TMA response (6\u00a0weeks) than in patients who did (114\u00a0weeks). Multivariate analysis suggested that the time from the most recent TMA episode\u00a0to start of\u00a0eculizumab treatment was negatively associated with kidney function improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No unexpected safety signals of eculizumab were identified in Japanese patients with aHUS in a real-world setting. Renal outcomes were negatively associated with the time from the most recent TMA episode\u00a0to the initiation of eculizumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-024-01921-y","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T11:02:25Z","timestamp":1716980545000},"page":"2181-2190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance"],"prefix":"10.1093","volume":"37","author":[{"given":"Shoichi","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"1921_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10157-016-1276-6","volume":"20","author":"H Kato","year":"2016","unstructured":"Kato H, Nangaku M, Hataya H et al (2016) Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20:536\u2013543","journal-title":"Clin Exp Nephrol"},{"key":"1921_CR2","doi-asserted-by":"crossref","unstructured":"Afshar-Kharghan V (2016) Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 217\u2013225","DOI":"10.1182\/asheducation-2016.1.217"},{"key":"1921_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","volume":"55","author":"F Fakhouri","year":"2018","unstructured":"Fakhouri F, Loirat C (2018) Anticomplement treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol 55:150\u2013158","journal-title":"Semin Hematol"},{"key":"1921_CR4","first-page":"2","volume":"11","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller H, Mannucci PM et al (2016) Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol Suppl 11:2\u201315","journal-title":"Clin Adv Hematol Oncol Suppl"},{"key":"1921_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5551\/jat.RV17026","volume":"26","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Kato H, Ikeda Y et al (2019) Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb 26:99\u2013110","journal-title":"J Atheroscler Thromb"},{"key":"1921_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","volume":"24","author":"E Bresin","year":"2013","unstructured":"Bresin E, Rurali E, Caprioli J et al (2013) European Working Party on Complement Genetics in Renal Diseases: combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475\u2013486","journal-title":"J Am Soc Nephrol"},{"key":"1921_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"key":"1921_CR8","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859","journal-title":"Clin J Am Soc Nephrol"},{"key":"1921_CR9","first-page":"1614","volume":"6","author":"G Ardissino","year":"2021","unstructured":"Ardissino G, Longhi S, Porcaro L et al (2021) Risk of atypical HUS among family members of patient carrying complement regulatory gene abnormality. KI Rep 6:1614\u20131621","journal-title":"KI Rep"},{"key":"1921_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0034-1375296","volume":"40","author":"S de Rodr\u00edguez","year":"2014","unstructured":"de Rodr\u00edguez S, Hidalgo MS, Pinto S et al (2014) Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 40:422\u2013430","journal-title":"Semin Thromb Hemost"},{"key":"1921_CR11","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392\u20132400","journal-title":"J Am Soc Nephrol"},{"key":"1921_CR12","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10157-018-1549-3","volume":"22","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M, Kato H, Yoshida Y et al (2018) Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 22:1088\u20131099","journal-title":"Clin Exp Nephrol"},{"key":"1921_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/IJNRD.S215370","volume":"12","author":"R Raina","year":"2019","unstructured":"Raina R, Grewal MK, Radhakrishnan Y et al (2019) Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 12:183\u2013204","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"1921_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10157-018-1609-8","volume":"23","author":"H Kato","year":"2019","unstructured":"Kato H, Miyakawa Y, Hidaka Y et al (2019) Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 23:65\u201375","journal-title":"Clin Exp Nephrol"},{"key":"1921_CR15","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179-184","journal-title":"Nephron Clin Pract"},{"key":"1921_CR16","unstructured":"Soliris package insert version 8. https:\/\/www.info.pmda.go.jp\/go\/pack\/6399424A1023_1_18\/. Accessed 20 Jan 2023"},{"key":"1921_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J, Yamamoto M, Hayashi S et al (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632\u2013639","journal-title":"N Engl J Med"},{"key":"1921_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi MP, Marantz JL et al (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297\u2013310","journal-title":"Br J Haematol"},{"key":"1921_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"1921_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01465-z","author":"JM Halimi","year":"2022","unstructured":"Halimi JM, Al-Dakkak I, Anokhina K et al (2022) Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-022-01465-z","journal-title":"J Nephrol"},{"key":"1921_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","volume":"14","author":"G Bayer","year":"2019","unstructured":"Bayer G, von Tokarski F, Thoreau B et al (2019) Etiology and outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol 14:557\u2013566","journal-title":"Clin J Am Soc Nephrol"},{"key":"1921_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"JV Walle","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G et al (2017) Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 30:127\u2013134","journal-title":"J Nephrol"},{"key":"1921_CR23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018833","volume":"142","author":"V Brocklebank","year":"2023","unstructured":"Brocklebank V, Walsh PR, Smith-Jackson K et al (2023) Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood 142:1371\u20131386","journal-title":"Blood"},{"key":"1921_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N et al (2019) Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher 34:171\u2013354","journal-title":"J Clin Apher"},{"key":"1921_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/1744-9987.13749","volume":"25","author":"T Abe","year":"2021","unstructured":"Abe T, Matsuo H, Abe R et al (2021) The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis. Ther Apher Dial 25:728\u2013876","journal-title":"Ther Apher Dial"},{"key":"1921_CR26","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40620-021-01025-x","volume":"34","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Scully M, Ardissino G et al (2021) Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol 34:1581\u20131590","journal-title":"J Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-01921-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:28Z","timestamp":1777564408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/8\/2181\/8306296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-01921-y","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"27 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Maruyama received honoraria for lectures and participation on advisory board from Alexion Pharma GK. S. Kaname received honoraria for lectures and participation on advisory board from Alexion Pharma GK. M. Matsumoto received honoraria for lectures and participation on advisory board from Alexion Pharma GK. Y. Miyakawa received research grant, clinical trials, and honoraria for participation on advisory board from Alexion Pharma GK. Y. Ishikawa. and A. Shimono are employees of Alexion Pharma GK and shareholders of Alexion Pharmaceutical Inc. All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Post-marketing surveillance was mandated by the Japanese government as part of the regulatory approval of eculizumab for aHUS in Japan. Post-marketing surveillance was conducted in accordance with Good Post-Marketing Study Practice (Ministry of Health, Labour and Welfare, Ministerial Ordinance No. 171 of 2004) to evaluate the safety and effectiveness of eculizumab in clinical practice. Ethical approval by an institutional review board is not mandatory for post-marketing surveillance.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures followed were in accordance with the Helsinki Declaration of 1964 and later versions. This article does not contain any studies with animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent from individual patients is not mandatory for post-marketing surveillance.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Infomed consent"}}]}}